TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial
Pol Specenier(Antwerp University Hospital), Jan B. Vermorken(University of Antwerp), Ahmad Awada(Centre Hospitalier Interrégional Edith Cavell), Cristiana Bergamini(Fondazione IRCCS Istituto Nazionale dei Tumori), Éva Remenár(National Institute of Oncology), Jessica Menis(University of Verona), Lisa Licitra(University of Milan), Catherine Fortpied(European Organisation for Research and Treatment of Cancer), Paul M. Clément(Universitair Ziekenhuis Leuven), Dirk Schrijvers(ZNA Middelheim Hospital), Jan Buter
Cited by 19
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994